Glaukos Co. (NYSE:GKOS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in Glaukos Co. (NYSE:GKOS - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,402 shares of the medical instruments supplier's stock after selling 4,809 shares during the quarter. Victory Capital Management Inc. owned approximately 0.13% of Glaukos worth $11,156,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock worth $284,501,000 after buying an additional 1,630,270 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock valued at $83,609,000 after acquiring an additional 207,338 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier's stock worth $87,776,000 after acquiring an additional 119,527 shares in the last quarter. State Street Corp lifted its stake in shares of Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock worth $254,626,000 after purchasing an additional 98,109 shares during the last quarter. Finally, First Turn Management LLC bought a new stake in Glaukos during the third quarter valued at about $12,520,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 3,328 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,744 shares of company stock valued at $2,504,131. Company insiders own 6.40% of the company's stock.

Glaukos Stock Performance

Shares of Glaukos stock traded up $0.93 during trading on Monday, hitting $103.12. 747,511 shares of the company's stock were exchanged, compared to its average volume of 578,272. Glaukos Co. has a 52-week low of $85.04 and a 52-week high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $5.83 billion, a price-to-earnings ratio of -35.93 and a beta of 0.99. The business has a 50-day simple moving average of $140.86 and a 200-day simple moving average of $137.69.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. On average, research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on GKOS. Wells Fargo & Company increased their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and increased their price objective for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens upgraded Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. Stifel Nicolaus increased their price target on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Finally, BTIG Research raised their price target on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.